A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. This year’s metric has recorded a Price increase of 16.82%. However, over the past six months, we’ve seen a weaker performance of 43.50%. The price of BMY fallen by 7.48% over the last 30 days. And in the last five days, it has surged by 1.82%.
Bristol-Myers Squibb Co experienced a rather steady stock market performance. The highest value in the past year was recorded at $61.08 on 11/11/24 and the lowest value was $39.35 on 07/05/24.
52-week price history of BMY Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Bristol-Myers Squibb Co’s current trading price is -1.87% away from its 52-week high, while its distance from the 52-week low is 52.33%. The stock’s price range during this time has been between $39.35 and $61.08. The trading volume for the Healthcare sector company’s shares reached about 9.03 million for the day, which was lower than the average daily volume of 11.08 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Bristol-Myers Squibb Co (BMY) has experienced a quarterly rise of 18.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 121.47B and boasts a workforce of 34100 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 51.06, with a change in price of +19.19. Similarly, Bristol-Myers Squibb Co recorded 12,327,068 in trading volume during the last 100 days, posting a change of +47.09%.
BMY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BMY stands at 3.00. Similarly, the long-term debt-to-equity ratio is also 2.93.
BMY Stock Stochastic Average
Today’s raw stochastic average for Bristol-Myers Squibb Co over the last 50 days is 90.48%.This indicates a increase from the raw stochastic average of the past 20 days, which was 83.97%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 77.91% and 76.08%, respectively.
